Anupam Rasayan intends to grow its annual revenue to ₹3,500 Crore by FY31, with a compound annual growth rate (CAGR) of 20-25%. To achieve this goal, the company plans to pursue strategic acquisitions and diversification.

Anupam Rasayan aims for robust expansion in Europe and the U.S., anticipating growth in those markets. Bliss GVS intends to broaden capacity, targeting EBITDA margins of over 20% with a ₹300 crore deal funded primarily through debt, focusing on expansion.

Anupam Rasayan's Q4 net profit decreased slightly to ₹427 million from ₹446 million last year, but the company still managed a significant 28% increase in revenue for the quarter at ₹6.4 billion compared to the previous year.

Anupam Rasayan experiences a 4.3% decrease in Q4 FY26 net profit as reported, with the financial data revealing declines compared to previous quarters and years. The report emphasizes this dip in both quarterly and yearly sales and profits.

Anupam Rasayan experienced a significant sales increase of 65% Year-on-Year, reaching ₹23,836 million in annual revenue. Along with a 32% rise in EBITDA and a 39% growth in Profit After Tax (PAT) to ₹2,222 million, the company also acquired Jayhawk Fine Chemicals and signed a deal with Bliss GVS Pharma, demonstrating strategic expansion.

Anupam Rasayan plans to purchase a significant stake (74.2%) in Bliss GVS Pharma for approximately INR 2198.5 crore, strengthening its presence within the pharmaceutical industry, as each share will be bought at INR 299.

Anupam Rasayan will release its FY26 financial results on May 23, 2026. The board meeting also aims to declare a final dividend and raise INR 160 crore through Non-Convertible Debentures (NCDs) via private placement.